Deutsche Bank AG Lowers Position in Boston Scientific Corporation $BSX

Deutsche Bank AG lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 15.0% during the 4th quarter, HoldingsChannel reports. The firm owned 6,748,180 shares of the medical equipment provider’s stock after selling 1,190,027 shares during the quarter. Deutsche Bank AG’s holdings in Boston Scientific were worth $643,439,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of BSX. Norges Bank purchased a new stake in Boston Scientific in the 4th quarter worth approximately $2,199,395,000. Egerton Capital UK LLP boosted its position in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Alphinity Investment Management Pty Ltd purchased a new stake in Boston Scientific in the 4th quarter worth approximately $252,918,000. Marshall Wace LLP boosted its position in Boston Scientific by 30.7% in the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after purchasing an additional 2,301,383 shares in the last quarter. Finally, Credit Agricole S A purchased a new stake in Boston Scientific in the 3rd quarter worth approximately $204,812,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by insiders.

Boston Scientific Trading Up 0.4%

Shares of BSX stock opened at $48.92 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market cap of $72.71 billion, a price-to-earnings ratio of 20.47, a PEG ratio of 0.91 and a beta of 0.56. The stock has a 50 day simple moving average of $57.28 and a 200-day simple moving average of $75.83. Boston Scientific Corporation has a 1-year low of $47.17 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Barclays lowered their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Bank of America lowered their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Mizuho reduced their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Finally, Citigroup reduced their target price on Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $85.92.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.